Last reviewed · How we verify

Azithromycin Oral Product — Competitive Intelligence Brief

Azithromycin Oral Product (Azithromycin Oral Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious Disease.

marketed Macrolide antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Azithromycin Oral Product (Azithromycin Oral Product) — Thomas Jefferson University. Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby stopping bacterial growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Azithromycin Oral Product TARGET Azithromycin Oral Product Thomas Jefferson University marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Oral Suspension Tedizolid Phosphate Oral Suspension Tedizolid Phosphate Merck Sharp & Dohme LLC marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit
QS azithromycin tablets QS azithromycin tablets University of Taubate marketed Macrolide antibiotic Bacterial 50S ribosomal subunit
Linezolid (L) Linezolid (L) Shenzhen Third People's Hospital marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit
clarithromycin, rifabutin clarithromycin, rifabutin The University of Texas Health Science Center at Tyler marketed Macrolide antibiotic and rifamycin antibiotic combination Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
PRISTINAMYCIN XRP7263 PRISTINAMYCIN XRP7263 Sanofi marketed Macrolide antibiotic / Streptogramin Bacterial 50S ribosomal subunit
Topical Clindamycin Topical Clindamycin University of Toronto marketed Lincosamide antibiotic Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

  1. Pfizer · 6 drugs in this class
  2. Grünenthal GmbH · 4 drugs in this class
  3. Merck Sharp & Dohme LLC · 3 drugs in this class
  4. University of Taubate · 2 drugs in this class
  5. Lihir Medical Centre · 2 drugs in this class
  6. Thomas Jefferson University · 2 drugs in this class
  7. Copenhagen Studies on Asthma in Childhood · 1 drug in this class
  8. Ain Shams Maternity Hospital · 1 drug in this class
  9. Celltrion · 1 drug in this class
  10. London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azithromycin Oral Product — Competitive Intelligence Brief. https://druglandscape.com/ci/azithromycin-oral-product. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: